DRUG DEVELOPMENT
BASED ON VITALLIFE PROGRAM OF 20 YEARS, WE ARE NOW DEVELOPING FDA-APPROVED MEDICINES TO IMPROVE YOUTHFULNESS, HEALTHSPAN AND LONGEVITY
NOW DEVELOPING INNOVATIVE MEDICINES FOR UNMET MEDICAL NEEDS
IMPACTING GLOBAL HEALTH WITH MULTIPLE DRUG CANDIDATES IN PIPELINE FOR ACCELERATED FDA-APPROVAL & MARKET
We are dedicated to developing FDA-approved therapeutics to make significant differences in the lives of patients with unmet medical needs.
​
Guided by our core purpose of positively impacting lives of patients and their families diagnosed with chronic diseases, including neuropsychiatric conditions, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, physicians and organizations engaged in helping patients worldwide. We work collaboratively across everything we do to achieve positive outcome in the lives of patients and their families.​
By Improving Mitochondrial Function And Inhibiting Chronic Systemic Inflammation, Our Drug Candidates Treat The Root Cellular Causes (Instead of Simply Controlling Symptoms) Illnesses such as Sarcopenia, Cognitive Impairment, Concussions And TBI. This Approach Provides Solutions For Long-Term Complications Of Diseases.
​
VitalLife Bio Inc. Has Expansive Pipeline Of Dug Development Candidates That Are Being Developed For FDA’s Unique Pathways, Including Fast-Track Submissions.
​
​
THREE Fast-Track Drug Product Candidates Ready For Clinical Development:
​
KEY FEATURES: All three drug candidates have Existing Human Data for Efficacy and Safety. And, all three are being developed for FDA's strategic fast-track pathways.
​
-
COGNIIQ, has positive human efficacy and safety data in early dementia/Mild Cognitive Impairment (MCI) , a $600 B global market. Cogniiq helps MCI in patients with medical conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Frontotemporal dementia (FTD), schizophrenia, Traumatic Brain Injury (TBI) and other neurodegenerative diseases.
​
-
EVENZYL is being developed for the treatment of Erectile Dysfunction (ED) in men, a $20B global market. It is safe, effective and proven in patients with ED.
​
-
VLB-710 is being developed for the treatment of sarcopenia, especially in patients with cancer, HIV and other chronic illnesses.
Strategic FDA Regulatory Pathways Provide Lower Cost, Accelerated Timeline, Lower Risk And With Higher Rates Of Success. We are utilizing FDA’s Special Fast-Track Pathway And Emergency Use Authorization (EUA)​​
